Saliva-based Detection of CD44



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/26/2018
Start Date:April 14, 2017
End Date:May 30, 2020
Contact:Roxanne Habbaba
Email:rhabbaba@ucsd.edu
Phone:858-534-6639

Use our guide to learn which trials are right for you!

A Prospective, Multi-site Trial of a Point of Care Saliva Based Detection Test Based on Soluble CD44 (OncAlert) for Presence of Disease in Previously Untreated Oral Cavity and Oropharynx Squamous Cell Carcinoma

The purpose of this study is to test the ability of OncAlert™ to screen for cancer and the
reappearance of cancer. OncAlert™ was developed by Vigilant Biosciences, a collaborator in
this research study. OncAlert™ is an oral rinse which is spit into a cup and sent to a
laboratory for analysis. OncAlert™ is considered experimental by the FDA because it is not
approved for the screening of cancer.

A noninvasive point of care salivary rinse test performed as 1) a one-time test for control
subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral
cavity/oropharynx cancer patients

Inclusion Criteria:

- Patient has the ability to understand and the willingness to sign a written informed
consent.

- Previously untreated, measurable squamous cell carcinoma of the oral cavity or
oropharynx with no evidence of distant metastasis, T1-4N0-3M0

- No prior history of treated upper aerodigestive tract cancer

- No concurrent, second, active malignancy other than oral cavity and/or oropharynx
cancer

- Planned to undergo treatment with curative intent

- Able to follow up after therapy at 3, 6, 12, and 18 months after completion of therapy
during routine post treatment follow up

- For control subjects: no evidence or history of upper aerodigestive tract cancer

- For control subjects: absence of any suspected or confirmed active malignancy at time
of enrollment

- Patients may have had prior therapy for malignancy other than upper aerodigestive
malignancy completed 2 years prior to enrollment if they have been disease free since
completion of therapy

- Patient is ≥ 18 years of age.

- Both men and women of all races and ethnic groups are eligible for this trial.

- Performance Status ≤ ECOG 3

- Patient is able to gargle and spit 5 cc of saline

- Patients may be concurrently enrolled in other therapeutic or detection clinical
trials

Exclusion Criteria:

- Prior completed therapy for an upper aerodigestive tract cancer within the past 3
years.

- Patient unable to gargle and spit 5 cc of saline, or anticipated to be unable to
gargle and spit after completion of therapy

- Patient unable or does not intend to undergo curative therapy

- Patient with concurrent, second primary malignancy under active therapy or completed
therapy within 2 years prior to enrollment.
We found this trial at
4
sites
La Jolla, California 92093
Principal Investigator: Joseph Califano, MD
Phone: 858-534-6639
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Baltimore, Maryland 21287
Phone: 410-502-8209
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
New York, New York 10019
?
mi
from
New York, NY
Click here to add this to my saved trials